Medtronic buys sleep apnea implant maker
This article was originally published in The Gray Sheet
Executive Summary
Medtronic gains Restore Medical's Pillar palatal implant system for treatment of obstructive sleep apnea and snoring through its $29 million acquisition of the company, announced April 22. The 510(k)-cleared device complements Medtronic ear, nose and throat products for "other upper airway obstructions, including the sinuses and tonsils/adenoids," according to the company (1"The Gray Sheet" Sept. 20, 2004, p. 18). St. Paul, Minn.-based Restore Medical had 2007 sales of $4.1 million, down 30%. The purchase deal values Restore at $1.60 per share - a 191% premium over its April 22 closing price of $0.55
You may also be interested in...
Sleep Apnea Surgery, CPAP Avoided By Palatal Implant – Restore Medical
Restore Medical will pursue Medicare and private insurer coverage for its Pillar palatal implant system by profiling the device's relative cost-effectiveness over surgical procedures to treat sleep apnea
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.